India's economic engine is revving up, but navigating the global headwinds requires sharp strategy. The rupee's recent volatility against the dollar underscores the complexities facing Indian businesses, impacting everything from import-export trade to domestic inflation. This week alone, we've seen significant shifts in the IT sector, with major players announcing restructuring and a renewed focus on AI-driven solutions. Meanwhile, the burgeoning startup ecosystem continues to attract substantial funding, despite a cautious global investor sentiment. The government's recent policy announcements on infrastructure development and digitalization are poised to further shape the business landscape, creating both opportunities and challenges for entrepreneurs and established corporations alike. Understanding these market dynamics is crucial for success in today's rapidly evolving Indian economy. Stay informed with Abtak.com for the latest insights and analysis on key sectors including finance, manufacturing, and technology – empowering your business decisions in a dynamic market. Explore the complete business news section now to stay ahead of the curve.
Hyderabad: CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, on Monday said it has reported positive top-line Phase 3 results for BP11, its investigational biosimilar to Xolair, or omalizumab.CuraTeQ said the study met all primary endpoints in patients with chronic spontaneous urticaria receiving the 300 mg dose, demonstrating high comparability with the reference product. The company said it plans to use the results to support regulatory submissions for chronic spontaneous urtica
Bengaluru: Biocon Limited has achieved a regulatory milestone in the United States, reinforcing its presence in the global diabetes treatment market. Biocon Pharma Limited, a subsidiary of Biocon Limited, has received approval from the U.S. Food and Drug Administration for Dapagliflozin Tablets in 5 mg and 10 mg strengths. The approval enables the company to market the drug for adults with type 2 diabetes mellitus, expanding its footprint in one of the world's largest pharmaceutical markets. The approved drug is indicated as an adjunct to diet and exercise to improve glycemic control in adul ...Read More >
Lucknow: This Diwali, residents of the city were exposed to decibel levels equivalent to noise made by a food blender switched on for hours. On Diwali night, noise levels exceeded standards at all sites, with highest value of 89.3 decibels (dB(A)) at Vikasnagar and the lowest of 75.8 dB (A) at Chowk on Diwali night, stated Indian Institute of Toxicology Research's air and noise quality assessment report for Lucknow during Diwali 2025, released on Thursday.Compared to the day before Diwali, noise levels at all four locations monitored by IITR increased by more than 15 units. After Vikasnagar, A ...Read More >
NEW DELHI, Apr 4 : "International Diabetes Federation" (IDF) President-elect, Dr Niti Pall, currently on India visit, called on Union Minister Dr Jitendra Singh, who is also a noted Professor of Medicine & Diabetes, and discussed, among other things, indigenous biosimilar Insulin production as well as Diabetes related indigenous biomanufacturing prospects. The meeting underscored the importance of strengthening India's capabilities in insulin manufacturing, particularly biosimilar insulins and Continuous Glucose Monitoring (CGM) instruments. The discussion brought into focus growing global c ...Read More >
New Delhi, Jun 27 (PTI) Biocon Ltd on Friday said its arm Biocon Biologics has been granted a notice of compliance by Health Canada for its biosimilar Yesafili injection used to treat various ailments of the eye. "Health Canada has granted a Notice of Compliance (NOC) for Yesafili(aflibercept), a biosimilar to Eylea injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL on June 26, 2025," a regulatory filing by Biocon said. This approval paves the way for the launch of Yesafili in Canada, scheduled for July 4, 2025, it said, adding Yesafili is the first biosimilar to Eylea to b ...Read More >
New Delhi, Oct 9 (PTI) Drug firm Lupin on Thursday announced the launch of a strategic partnership programme aimed at expanding the reach of a long-acting injectable platform developed by its subsidiary, Nanomi BV. The platform, PrecisionSphere demonstrates efficacy and safety in drug delivery and is ready for commercial use, following the recent US Food and Drug Administration (USFDA) approval for the first product developed with this platform. The company's partnership programme is designed to foster collaborations with companies looking to extend their product lifecycles, whether in devel ...Read More >
New Delhi, Jul 3 (PTI) Biocon Ltd on Thursday said its arm Biocon Biologics Ltd has been granted marketing authorisation by the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab used in the treatment of different bone diseases. The marketing authorisation for the European Union (EU) follows a positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025, Biocon Ltd said in a regulatory filing. Vevzuo is authorised for the prevention of bone complications in adults with advanced cancer involving bone and th ...Read More >
New Delhi, April 4 (SocialNews.XYZ) Union Minister Dr Jitendra Singh met with International Diabetes Federation President-elect Dr Niti Pall, and the latter highlighted that Asian and African countries "are increasingly looking to India for affordable diabetes care solutions," due to leadership in supplying cost-effective vaccines, an official statement said on Saturday. Dr Singh and Dr Pall discussed indigenous biosimilar insulin production and diabetes related indigenous biomanufacturing prospects, the Ministry of Earth Sciences said in a statement. She pointed out that high insulin prices ...Read More >
Biologic therapies are transforming severe asthma treatment by offering the potential for remission, shifting care from symptom control to targeted, personalized approaches. Treatments like dupilumab and tezepelumab have shown efficacy across diverse patient profiles, including complex asthma cases. However, significant barriers remain, particularly cost and access, limiting their availability, especially in underserved communities. Experts stress the need for equitable healthcare solutions to ensure these transformative treatments reach all patients in need. As biologics continue to revolutio ...Read More >
New Delhi, Aug 12 (PTI) Drug firm Lupin on Tuesday said it has partnered with Switzerland-based Sandoz Group AG to commercialise its biosimilar ranibizumab across multiple regions. Under the terms of the agreement, Sandoz will oversee commercialisation of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia, the Mumbai-based drug maker said in a statement. Lupin will be responsible for manufacturing the product and for regulatory submissions, it added. As per the deal, Sandoz will hold exclusive marketing rights in most ...Read More >
New Delhi, Oct 16 (PTI) Shares of pharmaceutical company Rubicon Research Ltd on Thursday listed with a premium of nearly 28 per cent against the issue price of Rs 485. The stock started trading at Rs 620.10, up 27.85 per cent, from the issue price on the BSE. At the NSE, the stock made its debut at Rs 620, registering a jump of 27.83 per cent. The company's market valuation stood at Rs 9,917.97 crore. The initial public offer of Rubicon Research garnered 103.90-times subscription on the closing day of bidding on Monday. The Rs 1,377.5-crore IPO had a price band of Rs 461-485 per share. ...Read More >
Mumbai, Oct 31 (SocialNews.XYZ) Actress Deepika Padukone, who has been a strong advocate for mental health awareness, reacted to cricketer Jemimah Rodrigues' recent revelation about battling anxiety. The 'Om Shanti Om' actress, known for openly sharing her own struggles with depression in the past, praised Jemimah for her honesty and courage in speaking up, highlighting the importance of conversations around mental well-being in sports and beyond. Taking to her Instagram Stories, Deepika Padukone reshared a video of cricketer Jemimah Rodrigues, in which the athlete opened up about her struggl ...Read More >
First & only immuno-oncology drug approved by various regulatory authorities around the world Dr. Reddy's Laboratories has announced the launch of Toripalimab in India. Toripalimab is a New Biological Entity (NBE). It is the only immuno-oncology drug approved by various regulatory authorities around the world such as United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In 2023, Dr. Reddy's entered in ...Read More >
Hyderabad, April 6 (RAHNUMA): CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has announced positive top-line results from its Phase 3 trial of BP11, an investigational biosimilar to Omalizumab (marketed as Xolair). The study met all primary endpoints, demonstrating strong comparability with the reference drug in treating chronic spontaneous urticaria (CSU) at a 300 mg dose. Conducted across 608 patients at nearly 80 sites in Europe and India, the trial showed precise equivalence in itch severity reduction at Week 12, aligning with requirements of both the Food and Drug Administration an ...Read More >
New Delhi, Apr 7 (PTI) Biocon Ltd on Tuesday announced the commercial launch of biosimilars Bosaya and Aukelso, indicated for different serious bone conditions, in the US. Bosaya (biosimilar to Prolia) and Aukelso (biosimilar to Xgeva) are now available by prescription nationwide through specialty pharmacies and healthcare providers, Biocon said in a statement. Both products have been previously approved and granted interchangeable designation by the US Food and Drug Administration in September 2025, allowing substitution at the pharmacy level in accordance with state laws, it added. "The US ...Read More >
New Delhi: Biocon Ltd on Tuesday announced the commercial launch of biosimilars Bosaya and Aukelso, indicated for different serious bone conditions, in the US. Bosaya (biosimilar to Prolia) and Aukelso (biosimilar to Xgeva) are now available by prescription nationwide through specialty pharmacies and healthcare providers, Biocon said in a statement. Also Read: Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas Tambe Both products have been previously approved and granted interchangeable designation by the US Food and Drug Administration in September 20 ...Read More >
AstraZeneca, Pfizer, and Eli Lilly, major players in the pharmaceutical and vaccine sectors, are drawing renewed attention as investors consider the shifting political landscape. AstraZeneca's cancer treatments, including Imfinzi and Calquence, are driving strong revenue growth, while the company plans to launch up to 24 new products by 2030. Eli Lilly, bolstered by its diabetes treatments like Mounjaro and Zepbound, has seen impressive stock gains, despite recent guidance cuts. Pfizer, although facing volatility, is a solid value investment with strong long-term potential. These companies' ro ...Read More >
MUMBAI, India and NAPLES, Fla., Oct. 9, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of a strategic partnership program aimed at expanding the reach of PrecisionSphere™ - the long-acting injectable (LAI) platform developed by its subsidiary, Nanomi B.V. (Nanomi). PrecisionSphere™ demonstrates efficacy and safety in drug delivery and is ready for commercial use, following the recent United States Food and Drug Administration's (U.S. FDA) approval for the first product developed with th ...Read More >
Two-year-old Bain Brandon has type 1 diabetes and needs insulin to live. But even with health insurance, the price tag isn't cheap. A 1-month supply of insulin vials and a 3-month supply of backup pens for the Mississippi toddler cost his parents $194 last week, according to his mom, 29-year-old Marlee Brandon. They can afford it right now -- but she worries about the future. "One day, Bain will be an adult, and he won't be able to be on our insurance anymore," she said. "I feel like a lot of p ...Read More >
FDA Approves Kirsty (insulin aspart-xjhz), an Interchangeable Biosimilar to NovoLog BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India: July 15, 2025 -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (FDA) has approved Kirsty™ (Insulin Aspart-xjhz), 100 units/mL as the first and only interchangeable* biosimilar to NovoLog® (Insulin ...Read More >
New Delhi [India], October 31 (ANI): The U.S. Food and Drug Administration (FDA) has announced major steps to make it faster and less costly to develop biosimilar medicines, lower-cost "generic" alternatives to biologic drugs used to treat serious and chronic diseases. In a new draft guidance, the FDA has proposed major updates aimed at simplifying biosimilarity studies and reducing unnecessary clinical testing. The agency also launched a separate initiative to make it easier for biosimilars to be developed as interchangeable with brand-name biologics, allowing patients and pharmacists to ch ...Read More >
New Delhi, Jul 16 (PTI) Biocon Biologics on Wednesday said it has received approval from the US health regulator to market a diabetes treatment medication. The company, a unit of Biocon Ltd, has received approval from the US Food and Drug Administration (USFDA) for Kirsty as the first and only interchangeable biosimilar to NovoLog (Insulin Aspart). Kirsty is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. The medication will be available as a single-patient-use prefilled pen for subcutaneous use and a multipl ...Read More >